Metabolomic Technologies Inc. Recognized by Frost and Sullivan
Frost & Sullivan has recognized Metabolomic Technologies Inc. (MTI) with the 2014 North American Technology Innovation Leadership Award. The innovative technology is MTI’s metabolomic screening test, PolypDx™. This proprietary technology platform and algorithms detect benign adenomatous polyps, which are the precursor to colorectal cancer. Read more.
MTI is a spin-off company from the University of Alberta. The company was formed from a research program facilitated by Drs. Haili Wang and Richard Fedorak, who were interested in using the new science of metabolomics to explore how colorectal cancer and adenomatous (precancerous) polyps affected cellular metabolism. At MTI, we are committed to developing advanced metabolomic-based diagnostic tests for the management of chronic diseases or ‘high value’ diagnostics.
Their initial focus is on developing highly novel, patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer (CRC). CRC is a leading cause of death in North America, but is curable if identified through early screening processes. However, current fecal-based screening methodologies are suboptimal due to a lack of sensitivity and acceptability. Our flagship product, PolypDx™, a spot urine diagnostic test, innovatively offers a significantly higher sensitivity in detecting adenomatous polyps and thus significantly advances the prevention of CRC.
MTI was incorporated in May 2010 in Edmonton, Alberta, Canada, and is working with TEC Edmonton on the business development aspect.
See Company Presentation.
See Funders and Collaborators.